During the summer of 2021, the Delta variant was causing a surge in COVID-19 cases. Many people wondered if the vaccines were still holding up. A study looking at veterans at five VA medical centers found that the mRNA vaccines—like those from Pfizer and Moderna—continued to show high effectiveness at preventing COVID-19 hospitalizations during that time. The research tracked veterans from February through August 2021, a period when Delta became the dominant strain. It's important to note this was an observational study, meaning it looked at real-world data rather than a controlled experiment. The researchers didn't report specific numbers on exactly how much protection the vaccines provided, or how many people were involved. But the core finding—that effectiveness remained high—is a meaningful piece of evidence, especially for a population like veterans who may have other health conditions. The study didn't report on safety issues or side effects during this period.
COVID-19 mRNA vaccines show sustained effectiveness against hospitalization in U.S. veteransDid COVID-19 vaccines keep protecting veterans from hospitalization?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
An observational study conducted at five Veterans Affairs Medical Centers in the United States evaluated the effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalization among U.S. veterans. The study period spanned from February 1 to August 6, 2021, which included the spread of the Delta variant. The primary finding was that COVID-19 mRNA vaccine effectiveness 'remains high,' though the study did not report specific effect sizes, absolute numbers, confidence intervals, or p-values.
No safety, tolerability, or adverse event data were reported for this analysis. The study did not specify a comparator group, and the sample size was not reported.
Key limitations include the observational study design, which can only show association, not causation. The lack of reported quantitative data on vaccine effectiveness, such as hazard ratios or vaccine efficacy percentages, limits the precision of the findings. The population was restricted to U.S. veterans receiving care at VA facilities, which may not be fully generalizable to other populations.
For practice, this evidence suggests a continued association between mRNA vaccination and protection against severe COVID-19 outcomes in this specific veteran population during the observed period. However, clinicians should interpret these findings with appropriate caution due to the observational nature of the evidence and the absence of detailed numerical results.
More on COVID
View Original Abstract ↓
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
From Other Specialties
